467
edits
Heart Failure: Difference between revisions
no edit summary
No edit summary |
No edit summary |
||
| Line 605: | Line 605: | ||
[[Image:acute_hf_flowchart.svg|400px|thumb|'''Figure 7.''' Flowchart acute HF.]] | [[Image:acute_hf_flowchart.svg|400px|thumb|'''Figure 7.''' Flowchart acute HF.]] | ||
{| class="wikitable" border="0" cellpadding="0" cellspacing="0" width=" | {| class="wikitable" border="0" cellpadding="0" cellspacing="0" width="630px" | ||
|- | |- | ||
!colspan="3"|Table 6. Medication in acute heart failure | !colspan="3"|Table 6. Medication in acute heart failure | ||
| Line 683: | Line 683: | ||
Patient presents at first aid or emergency room with signs of acute HF. | Patient presents at first aid or emergency room with signs of acute HF. | ||
{| class="wikitable" border="0" cellpadding="0" cellspacing="0" width=" | {| class="wikitable" border="0" cellpadding="0" cellspacing="0" width="630px" | ||
|- | |- | ||
!colspan="3"|Table 7. Medication in chronic heart failure | !colspan="3"|Table 7. Medication in chronic heart failure | ||
| Line 695: | Line 695: | ||
| | | | ||
|- | |- | ||
| | |valign="top"| | ||
*Furosemide | *'''Furosemide''' | ||
|valign="bottom"| | |valign="bottom"| | ||
Renal failure | Renal failure | ||
| Line 703: | Line 703: | ||
80 mg – max 1000 mg | 80 mg – max 1000 mg | ||
|- | |- | ||
| | |valign="top"| | ||
*Bumetanide | *'''Bumetanide''' | ||
|valign="bottom"| | |valign="bottom"| | ||
Renal failure | Renal failure | ||
| Line 714: | Line 714: | ||
|- | |- | ||
|valign="top"| | |valign="top"| | ||
*Captopril | *'''Captopril''' | ||
| | | | ||
|Start:::6.25mg | |Start:::6.25mg | ||
| Line 725: | Line 725: | ||
|- | |- | ||
|valign="top"| | |valign="top"| | ||
*Lisinopril | *'''Lisinopril''' | ||
| | | | ||
|Start:::2.5-5mg | |Start:::2.5-5mg | ||
| Line 736: | Line 736: | ||
|- | |- | ||
|valign="top"| | |valign="top"| | ||
*Enalapril/quinalapril | *'''Enalapril/quinalapril''' | ||
| | | | ||
|Start:::2.5-5mg | |Start:::2.5-5mg | ||
| Line 749: | Line 749: | ||
|- | |- | ||
|valign="top"| | |valign="top"| | ||
*Metoprolol zoc (succinate) | *'''Metoprolol zoc (succinate)''' | ||
|valign="top"|EF >30-45% and NYHA II-III | |valign="top"|EF >30-45% and NYHA II-III | ||
|Start:::25mg | |Start:::25mg | ||
| Line 834: | Line 834: | ||
|bgcolor="#F0F0F0 " colspan="3"|'''Aldosterone antagonist''' | |bgcolor="#F0F0F0 " colspan="3"|'''Aldosterone antagonist''' | ||
|- | |- | ||
| | |valign="top"| | ||
*'''Spironolactone/eplerenone''' | *'''Spironolactone/eplerenone''' | ||
| | | | ||
| Line 851: | Line 851: | ||
potassium >5.5: stop | potassium >5.5: stop | ||
|- | |- | ||
|'''Digoxin''' | |valign="top"| | ||
*'''Digoxin''' | |||
| | | | ||
|Start:::0.5mg, 0.25mg and 0,25 mg, each with 6 hours in between | |Start:::0.5mg, 0.25mg and 0,25 mg, each with 6 hours in between | ||
| Line 861: | Line 862: | ||
|bgcolor="#F0F0F0 " colspan="3"|'''AT II blockers''' | |bgcolor="#F0F0F0 " colspan="3"|'''AT II blockers''' | ||
|- | |- | ||
| | |valign="top"| | ||
*'''Candesartan''' | *'''Candesartan''' | ||
| | | | ||
| Line 870: | Line 871: | ||
>7 weeks:::16mg once daily. | >7 weeks:::16mg once daily. | ||
|- | |- | ||
| | |valign="top"| | ||
*'''Valsartan''' | *'''Valsartan''' | ||
| | | | ||
| Line 881: | Line 882: | ||
|colspan="3" bgcolor="#F0F0F0 "|'''Hydralazine and isosorbide dinitrate (H-ISDN)''' | |colspan="3" bgcolor="#F0F0F0 "|'''Hydralazine and isosorbide dinitrate (H-ISDN)''' | ||
|- | |- | ||
| | |valign="top"| | ||
*'''Hydralazine''' | *'''Hydralazine''' | ||
| | | | ||
| Line 890: | Line 891: | ||
>7 weeks:::75-100mg three times daily. | >7 weeks:::75-100mg three times daily. | ||
|- | |- | ||
| | |valign="top"| | ||
*'''ISDN''' | *'''ISDN''' | ||
| | | | ||